AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia(APL)
In AIDA 2000 therapy of acute promyelocytic leukemia (APL) is given in a risk-adapted
manner. Risk factors are age and white-blood-cell (WBC)-count at diagnosis. Induction
therapy is done with ATRA and idarubicin followed by postremission therapy with daunorubicin
and mitoxantrone in age adapted dosages. Patients with an high WBC were additionally treated
with cytarabine. Finally a two year period of maintenance therapy with 6-mercaptopurine,
methotrexate and ATRA is performed.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
overall survival
Gerhard Ehninger, MD
Principal Investigator
Department of Medicine I, University Hospital Carl Gustav Carus Dresden
Germany: Federal Institute for Drugs and Medical Devices
MK1-192
NCT00180128
January 2000
November 2012
Name | Location |
---|